Cyclacel Pharmaceuticals, Inc. financial data

Symbol
CYCC, CYCCP on Nasdaq
Location
200 Connell Drive, Suite 1500, Berkeley Heights, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 210 % +153%
Debt-to-equity 75.5 %
Return On Equity -187 % -105%
Return On Assets -107 % +43.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.9M shares -22.1%
Common Stock, Shares, Outstanding 3.5M shares +62.5%
Entity Public Float 2.52M USD -55.1%
Common Stock, Value, Issued 3K USD +50%
Weighted Average Number of Shares Outstanding, Basic 1.91M shares +4180%
Weighted Average Number of Shares Outstanding, Diluted 1.91M shares +4180%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.72M USD -80%
General and Administrative Expense 1M USD -18.8%
Operating Income (Loss) -9.17M USD +41%
Nonoperating Income (Expense) 4.93M USD -60%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -4.24M USD +73.2%
Income Tax Expense (Benefit) 2K USD
Net Income (Loss) Attributable to Parent -5.44M USD +59.5%
Earnings Per Share, Basic 213 USD/shares +97%
Earnings Per Share, Diluted 213 USD/shares +97%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.84M USD +28.7%
Accounts Receivable, after Allowance for Credit Loss, Current 725K USD
Inventory, Net 1.37M USD
Other Assets, Current 460K USD +48.9%
Assets, Current 6.44M USD +31.2%
Property, Plant and Equipment, Net 129K USD +3125%
Operating Lease, Right-of-Use Asset 15K USD -70.6%
Goodwill 1.57M USD
Assets 8.16M USD +51.6%
Accounts Payable, Current 468K USD -88.7%
Accrued Liabilities, Current 534K USD -76%
Liabilities, Current 1M USD -84.2%
Operating Lease, Liability, Noncurrent 5K USD
Liabilities 1.06M USD -83.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -891K USD +1.87%
Retained Earnings (Accumulated Deficit) -444M USD -1.79%
Stockholders' Equity Attributable to Parent 7.1M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.63M USD +263%
Liabilities and Equity 8.16M USD +51.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.25M USD -572%
Net Cash Provided by (Used in) Financing Activities 3.65M USD
Common Stock, Shares Authorized 600M shares +500%
Common Stock, Shares, Issued 3.5M shares +62.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 313K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.14M USD -7.13%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4K USD
Deferred Tax Assets, Valuation Allowance 59.8M USD +4.36%
Deferred Tax Assets, Gross 59.8M USD +4.36%
Operating Lease, Liability 5K USD
Depreciation 2K USD -75%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.41M USD +66.9%
Lessee, Operating Lease, Liability, to be Paid 28K USD -48.1%
Property, Plant and Equipment, Gross 427K USD -0.47%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One 5K USD -92.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 59.4M USD +4.11%
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 0 USD -100%
Additional Paid in Capital 451M USD +3.4%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.77M USD +116%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%